According to the Securities Star data Center, Kaisai Biology 2021 reported that the company's main income was 1.014 billion yuan, up 27.83% from the same period last year; the net profit from its parent was 326 million yuan, up 58.12% from the same period last year; deducting 306 million yuan from non-net profit, up 47.4% from the same period last year; debt ratio 8.14%, investment income 4.9579 million yuan, financial expenses-75.6635 million yuan, gross profit 42.37%.
There are 8 new shareholders in this period. Bank of Communications Co., Ltd.-Great Wall Jiufu Core growth mixed Securities Investment Fund (LOF) holds 274378 shares, accounting for 0.68% of tradable shares. Shanghai Pudong Development Bank Co., Ltd.-Guangfa small-cap growth mixed Securities Investment Fund (LOF) holds 300000 shares, accounting for 0.75% of tradable shares. China Industrial and Commercial Bank of China Co., Ltd.-China Merchants quality upgrading mixed Securities Investment Fund holds 341158 shares, accounting for 0.85% of tradable shares, National Social Security Fund 602 portfolio holds 641194 shares, accounting for 1.59% of tradable shares. China Agricultural Bank Of China Co., Ltd.-Huitianfu reverse Investment mixed Securities Investment Fund holds 376665 shares, accounting for 0.94% of tradable shares. China Merchants Bank Co., Ltd.-Huaxia Shanghai Kechuang Board 50 component traded index securities investment fund holds 1.019879 million shares, accounting for 2.54% of tradable shares. China Industrial and Commercial Bank of China Co., Ltd.-Yi Fangda Shanghai Stock Exchange 50 component traded index securities investment fund holds 596852 shares, accounting for 1.48% of tradable shares, while Xue Xianghua holds 375438 shares. Accounts for 0.93% of tradable shares
For a summary of the financial report data, please see the following figure: